This review provides a summary of our current understanding of, and the controversies
surrounding, the diagnosis, pathogenesis, histopathology, and molecular biology of Barrett's …

Introduction The low incidence of oesophageal adenocarcinoma (EAC) in Barrett's
oesophagus (BE) patients reinforces the need for risk stratification tools to make BE …

METHODS: A single-blinded, case-control study was conducted to stratify patients with BE
as low, intermediate, or high risk for progression to HGD/EAC within 5 years using a …

METHODS: A blinded, retrospective cohort study was derived from the screening cohort of a
randomized controlled trial of SURveillance vs RadioFrequency ablation for BE patients with …

Background: Better methods are needed to predict risk of progression for Barrett's
esophagus. We aimed to determine whether a tissue systems pathology approach could …

Background: There is a need for improved tools to detect high-grade dysplasia (HGD) and
esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus. In previous work …

Barrett's esophagus is a widespread chronically progressing disease of heterogeneous
nature. A life threatening complication of this condition is neoplastic transformation, which is …

Barrett esophagus (BE) is a known risk factor for the development of esophageal
adenocarcinoma. Pathologists play a critical role in confirming the diagnosis of BE and BE …

Background: Current histologic methods for diagnosis are limited by intra-and inter-observer
variability. Immunohistochemistry (IHC) methods are frequently used to assess biomarkers …

Objective The diagnosis of dysplasia in Barrett's oesophagus (BO) can be challenging, and
reliable ancillary techniques are not available. This study examines if DNA content …